EUVIMEDEUVIMED entdecken
Open Access

BAP1-related signature predicts benefits from immunotherapy over VEGFR/mTOR inhibitors in ccRCC: a retrospective analysis of JAVELIN Renal 101 and checkmate-009/010/025 trials

Kan Liu, Yan Huang, Yu Xu, Guoqiang Wang, Shangli Cai, Xu Zhang, Taoping Shi

Cancer Immunology, Immunotherapy · 2023

DOI: 10.1007/s00262-023-03424-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2023. Verfasst von Kan Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Third Medical Center of PLA General Hospital, Yongding Road 69, Haidian District, Beijing, 100039, China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Antineoplastic Agents, Kidney Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Hainan Province Science and Technology Special Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellAntineoplastic AgentsKidney NeoplasmsHumansSunitinibAxitinibEverolimusMTOR InhibitorsNivolumabRetrospective StudiesImmunotherapyTumor MicroenvironmentTumor Suppressor ProteinsUbiquitin Thiolesterase

Stichwörter der Autor:innen

Clear cell renal cell carcinomaImmunotherapyPredictive biomarkerThe BAP1-score

Substanzen

SunitinibAntineoplastic AgentsAxitinibEverolimusMTOR InhibitorsNivolumabBAP1 protein, humanTumor Suppressor ProteinsUbiquitin Thiolesterase

Autor:innen und Institutionen

  • Department of Urology, The Third Medical Center of PLA General Hospital, Yongding Road 69, Haidian District, Beijing, 100039, China.
  • Burning Rock Biotech, Guangzhou, Guangdong, China.
  • Department of Urology, The Third Medical Center of PLA General Hospital, Yongding Road 69, Haidian District, Beijing, 100039, China. xzhang301@163.com.
  • Department of Urology, The Third Medical Center of PLA General Hospital, Yongding Road 69, Haidian District, Beijing, 100039, China. stopping3721@foxmail.com.

Förderung

  • National Natural Science Foundation of China
  • Hainan Province Science and Technology Special Fund

Zitieren

APA

Liu, K., Huang, Y., Xu, Y., Wang, G., Cai, S., Zhang, X., & Shi, T. (2023). BAP1-related signature predicts benefits from immunotherapy over VEGFR/mTOR inhibitors in ccRCC: a retrospective analysis of JAVELIN Renal 101 and checkmate-009/010/025 trials. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-023-03424-4

Vancouver

Liu K, Huang Y, Xu Y, Wang G, Cai S, Zhang X, et al. BAP1-related signature predicts benefits from immunotherapy over VEGFR/mTOR inhibitors in ccRCC: a retrospective analysis of JAVELIN Renal 101 and checkmate-009/010/025 trials. Cancer Immunology, Immunotherapy. 2023. doi:10.1007/s00262-023-03424-4

BibTeX
@article{Liu2023,
  author = {Liu, Kan and Huang, Yan and Xu, Yu and Wang, Guoqiang and Cai, Shangli and Zhang, Xu and Shi, Taoping},
  title = {BAP1-related signature predicts benefits from immunotherapy over VEGFR/mTOR inhibitors in ccRCC: a retrospective analysis of JAVELIN Renal 101 and checkmate-009/010/025 trials},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2023},
  doi = {10.1007/s00262-023-03424-4}
}
Kostenlos starten →